Condition: Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma · Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
This study aims to evaluate the efficacy and safety of SHR-A1811 combined with chemotherapy and immune checkpoint inhibitor versus standard first-line therapy in gastric or gastroesophageal junction adenocarcinoma.
This description comes directly from the study's public registry record.
Shi Wei SUN · +86 18036618554 · Shiwei.sun@hengrui.com
Always discuss trial participation with your own doctor first.
| The First Hospital of China Medical University | Shenyang, Liaoning, China | Recruiting |
| Zhongshan Hospital，Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07118527